Genome Editing Market to Grow with a CAGR of 16.65% through 2030
Rising Incidence of Genetic Disorders and Increase in Precision Medicine is expected to drive the Global Genome Editing Market growth in the forecast period, 2026-2030
According to TechSci Research report, “Genome
Editing Market – Global Industry Size, Share, Trends, Competition Forecast
& Opportunities, 2030”, the Global Genome Editing Market stood at USD 8.05
Billion in 2024 and is anticipated to grow with a CAGR of 16.65% in the
forecast period, 2026-2030.
The ongoing advancements in genome editing
technologies, particularly CRISPR-Cas9, have fundamentally reshaped the market
landscape. These innovations have significantly improved the precision,
efficiency, and ease of gene modification, facilitating their adoption across
diverse sectors, including healthcare, agriculture, and industrial
biotechnology. The enhanced capability to modify complex genes is driving the
development of genome-based therapies and treatments, expanding the potential
applications of genome editing. As these technologies continue to evolve, their
commercial applications are becoming increasingly broad, contributing to robust
market growth. Global investments in genomic
research and development are accelerating the commercialization of these
technologies. Governments are committing substantial financial resources to
support genome-editing research, recognizing its transformative potential in
addressing healthcare challenges, enhancing agricultural productivity, and
improving environmental sustainability. Collaborative efforts between public
institutions and private-sector players are fostering the development of novel therapeutic
solutions, as well as genetically modified crops. These investments not only
advance research capabilities but also facilitate regulatory approvals and
accelerate the market entry of innovative genome-editing applications.
In the agricultural biotechnology sector, genome
editing is playing a pivotal role in enhancing crop yields, improving disease
resistance, and boosting environmental stress tolerance. With rising concerns
over food security and the impact of climate change, the demand for genetically
modified crops with superior traits is intensifying. Genome editing presents a
precise and targeted alternative to traditional genetic modification methods,
making it a compelling tool for agricultural research and development. This
growing application is broadening the market for genome editing beyond
healthcare, opening new revenue streams in the agritech sector. As ethical debates surrounding genome
editing, especially germline editing, continue to evolve, regulatory bodies are
establishing clearer guidelines to address safety and ethical concerns. This
regulatory clarity is fostering greater acceptance and confidence in the use of
genome editing technologies across medical and agricultural applications. As
these frameworks progress, they are not only enhancing the safety and viability
of genome editing but also creating a more favorable environment for investment
and innovation, driving the continued expansion of the market.
Browse over XX market data Figures spread
through XX Pages and an in-depth TOC on "Global Genome Editing Market”
The Global Genome Editing Market is segmented into technology,
delivery mode, application, mode, end user, regional distribution, and company.
Based on its application, the Genetic Engineering segment
has emerged as the predominant market leader, The healthcare sector stands at
the forefront of genetic engineering’s dominance within the genome editing
market. Gene therapies using genome editing technologies are revolutionizing
the treatment of genetic disorders, including sickle cell disease, beta-thalassemia,
and cystic fibrosis, by enabling precise modifications of disease-causing
genes. The ability to edit defective genes at the DNA level allows for curative
therapies rather than symptomatic treatments, creating new pathways for the
treatment of previously untreatable genetic conditions. Additionally, genetic
engineering in oncology is expanding, with the use of genome editing tools to
modify immune cells for cancer immunotherapies. Technologies like CAR-T cell
therapy, which uses genetically modified immune cells to target cancer cells,
represent a growing application of genetic engineering in precision medicine.
This therapeutic revolution is gaining traction in clinical trials and is
expected to continue driving demand for genome editing solutions in healthcare.
As the market for genetic therapies expands, regulatory approvals and a more
supportive policy environment in key regions, such as the U.S. and Europe, are
encouraging innovation and accelerating the commercialization of these
therapies, further solidifying genetic engineering’s market leadership in the
genome editing space.
Based on its mode, the Contract segment has emerged as
the predominant market leader, The contract services segment plays an essential
role in supporting genome editing R&D activities by offering specialized
services in gene modification, cell line development, genomic screening, and
clinical trials. Genome editing technologies, such as CRISPR/Cas9, require
highly specialized knowledge and significant resources to optimize and
implement effectively. For many companies, outsourcing these tasks to Contract
Research Organizations (CROs) or Contract Development and Manufacturing
Organizations (CDMOs) provides a cost-effective and efficient way to access
cutting-edge technologies and expertise without the need to build their own
expensive infrastructure. Many biotech startups and smaller companies, which
may not have the resources for comprehensive in-house development, rely heavily
on contract services for critical stages of their genome editing workflows.
CROs and CDMOs offer a range of services, from early-stage research to the
clinical manufacturing of genome-edited therapies, creating a vital ecosystem
that supports the growth of the broader genome editing market.
As genome editing technologies advance to the point of
commercialization, companies face the challenge of scaling up from
laboratory-level research to full-scale production of genome-edited products.
This requires advanced manufacturing capabilities, regulatory expertise, and
infrastructure, all of which can be costly and time-consuming to develop
in-house. Contract manufacturing organizations (CMOs) play a pivotal role in
providing scalable production services, particularly for the biopharmaceutical
industry. These companies specialize in the manufacturing of gene-editing
therapies, ensuring compliance with stringent Good Manufacturing Practices
(GMP) and facilitating the rapid production of high-quality, safe products. By
outsourcing production to specialized CMOs, companies can significantly reduce
the time to market and minimize the financial burden associated with
large-scale production. This trend is particularly evident in the cell and gene
therapy space, where genome-edited therapies such as CAR-T cell therapies and
other gene-modified treatments are gaining traction. CDMOs offer turnkey
solutions for the end-to-end manufacturing process, from initial process
development to final clinical supply, driving growth in the contract segment
within the genome editing market.
The Asia Pacific region is experiencing rapid market
growth. Governments across the APAC region are increasingly recognizing the
strategic importance of genome editing technologies, particularly in healthcare
and agriculture, and are providing substantial support to foster innovation.
Countries like China, India, South Korea, and Japan have made significant
investments in genomics research and biotechnology development. China has been
a leader in adopting and advancing genome editing technologies, particularly in
genetic modification and gene therapies. The Chinese government has heavily
invested in genetic research and development (R&D) and has provided
favorable regulatory frameworks that promote genome editing applications,
particularly in agriculture and medicine. This policy support has accelerated
the commercialization of genome editing technologies in the region and
positioned China as a global hub for genomic research. India is focusing on
expanding its biotech sector, with an emphasis on agriculture and healthcare
innovation. The Indian government is providing financial incentives, policy
reforms, and institutional support to develop genome editing technologies that
address critical challenges, such as crop yields and disease prevention. This
favorable regulatory environment is expected to propel the market growth in the
region.
The Asia-Pacific region is home to a rapidly expanding
biotechnology ecosystem, which is vital to the growth of the genome editing
market. The region has seen a surge in the establishment of biotech companies,
research institutions, and universities focused on advancing CRISPR and other
genome editing technologies. Japan and South Korea are at the forefront of
biotechnology innovation, with well-established research infrastructures,
cutting-edge laboratories, and highly skilled researchers in the field of
genetic engineering. These countries are making significant strides in genomic
medicine and gene therapy development, with a strong emphasis on regenerative
medicine, cancer therapies, and genetic disorder treatments. The Indian
biotechnology sector has shown significant potential in developing
cost-effective genome editing solutions, particularly in agriculture and
healthcare. India’s established biotech hubs, such as Hyderabad and Bengaluru,
have attracted international investments, supporting the region’s emergence as
a critical player in genome editing technology.
Major companies operating in Global Genome
Editing Market are:
- Merck KGaA
- Cibus Inc.
- Danaher Corporation
- GenScript Biotech Corporation
- Thermo Fisher Scientific Inc
- Lonza Group Ltd
- Takara Bio Inc.
- AstraZeneca
- Precision BioSciences
- Sangamo Therapeutics, Inc
Download Free Sample Report
Customers can also request for 10% free customization
on this report.
“The global genome editing market is poised for
substantial growth, driven by continuous technological advancements, increasing
research investments, and expanding applications across healthcare,
agriculture, and industrial biotechnology. The market is benefitting from the
widespread adoption of powerful genome editing tools like CRISPR/Cas9,
advancements in precision medicine, and growing demand for genetically modified
crops and gene therapies. However, challenges related to ethical
considerations, regulatory hurdles, and costs remain, demanding ongoing
innovation and strategic collaborations to overcome these barriers. The
Asia-Pacific region is emerging as a key growth driver, leveraging cost
advantages, government support, and an expanding biotechnology ecosystem. As
the industry matures, the continued evolution of genome editing technologies,
coupled with strategic investments and regulatory developments, will enable the
market to thrive, unlock new opportunities, and deliver transformative
solutions for healthcare, agriculture, and beyond.,” said Mr. Karan Chechi,
Research Director of TechSci Research, a research-based management consulting
firm.
“Genome Editing Market - Global Industry Size,
Share, Trends, Opportunity & Forecast, Segmented By Technology
((CRISPR)/Cas9, TALENs/MegaTALs, ZFN, Meganuclease, Others), By Deliver Mode
(Ex-vivo, In-vivo), By Application (Genetic Engineering, Clinical
Applications), By Mode (Contract, In-house), By End User (Biotechnology and
pharmaceutical companies, Academic and government research institutes, Contract
research organizations), By Region, & Competition, 2020-2030F”, has evaluated the future growth potential of Global
Genome Editing Market and provides statistics & information on market size,
structure and future market growth. The report intends to provide cutting-edge
market intelligence and help decision makers take sound investment decisions.
Besides, the report also identifies and analyzes the emerging trends along with
essential drivers, challenges, and opportunities in Global Genome Editing
Market.
Contact
TechSci Research LLC
420 Lexington Avenue, Suite 300,
New York, United States- 10170
Tel: +1-332-258-6602
Email: [email protected]
Website: www.techsciresearch.com